VERTEX PHARMACEUTICALS INC / MA
For the period ended Dec 31, 2025. Filed Feb 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Corporate Headquarters
We lease approximately 1.1 million square feet of office and laboratory space at our corporate headquarters in Boston,
Massachusetts in two buildings pursuant to two leases that we entered into in May 2011 and amended in August 2024 to,
among other terms, extend the lease termination dates from December 2028 to June 2044. We have the option to extend the
term of the leases for up to two additional ten-year periods.
Additional United States and Worldwide Locations
In addition to our corporate headquarters, we lease an aggregate ofapproximately 865,000 square feet of space globally.
This space includes logistical, laboratory, commercial and manufacturing operations, as well as laboratory and office space to
support our research and development organizations. We also own approximately 213,000 square feet at our continuous
manufacturing facility in Massachusetts. Additionally, we are constructing the second building of our Leiden Campus in
Massachusetts (“Leiden II”), which will include approximately 348,000 square feet of office and laboratory space. We expect
Leiden II to be operational in late 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.